Escitalopram plus tandospirone significantly decreased HAMD scores by 3.97 to 5.85 at week 2 and PHQ-15 scores at week 12 in patients with vascular depression compared to monotherapy.
Does escitalopram plus tandospirone citrate improve anxiety, depression, and somatization symptoms compared to escitalopram alone in patients with vascular depression?
The combination of escitalopram and tandospirone citrate significantly improves anxiety, depression, and somatization symptoms in patients with vascular depression compared to escitalopram alone.
Absolute Event Rate: 0% vs 0%
BACKGROUND: Mood disorders are important clinical manifestations of vascular depression (VaDep). We explored the efficacy of escitalopram plus tandospirone citrate in treating VaDep and the involvement of blood neurotransmitters during the treatment. METHODS: This single-center, double blind, randomized controlled study randomly divided patients with VaDep into Monotherapy group (escitalopram + placebo) or Combined group (escitalopram + tandospirone citrate). The primary outcome measures were the changes in psychological assessment scales from baseline to week 12, including the Hamilton Anxiety Scale (HAMA), Hamilton Depression Rating Scale (HAMD), Patient Health Questionnaire-15 (PHQ-15), Somatic Symptom Scale (SSS). RESULTS: Compared with the Monotherapy group, the Combined group reported a significant decrease in the HAMD score at post-treatment week 2 (95 % CI 3.97 to 5.85, p < 0.001), in the PHQ-15 score at post-treatment weeks12 (95 % CI 0.54 to 1.37, p < 0.001), and increased in platelet 5-HT CONCLUSION: Combination treatment significantly improves anxiety, depression, and somatization symptoms in patients with VaDep in which platelet 5-HT
Zeng et al. (Mon,) reported a other. Escitalopram plus tandospirone significantly decreased HAMD scores by 3.97 to 5.85 at week 2 and PHQ-15 scores at week 12 in patients with vascular depression compared to monotherapy.